Trial Profile
Oral Anti-CD3 for the Treatment of Active Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Muromonab CD3 (Primary) ; Omeprazole
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacodynamics
- 24 Jun 2019 According to a Tiziana Life Sciences media release, this study was conducted in Harvard Medical School, also.
- 24 Jun 2019 According to a Tiziana Life Sciences media release, this study were published at in the peer reviewed journal Crohns & Colitis 360.
- 09 May 2013 Planned end date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov